Evidence map›Paper›PMID 40536492›Full record

Trial reportInternational journal of cancer2025

Twenty-year survival outcomes after multipeptide vaccination for resected high-risk melanoma: A post-hoc analysis of a randomized clinical trial.

Emily K Ninmer, Hong Zhu, Kimberly A Chianese-Bullock, Craig L Slingluff

Registry-linked trialAbstract readRandomized Controlled TrialClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in International journal of cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00938223 (This is an Open-label, Phase II Study of a Vaccine Comprising Melanoma Peptides and a Tetanus Helper Peptide, Administered in GM-CSF-in-adjuvant. Patients Will be Randomized to Receive One of Two Different Vaccine Regimens. Patients Will be Stratified by Stage of Disease), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00938223 phase2completednot on this map

This is an Open-label, Phase II Study of a Vaccine Comprising Melanoma Peptides and a Tetanus Helper Peptide, Administered in GM-CSF-in-adjuvant. Patients Will be Randomized to Receive One of Two Different Vaccine Regimens. Patients Will be Stratified by Stage of Disease (IIB vs. III vs. IV).

TypeinterventionalSponsorCraig L Slingluff, JrRan2000Enrolled51ConditionsMelanomaArms4-peptide and 12-peptide melanoma vaccines
3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Trial
  2. Cellular immunotherapy in melanoma: the next frontier in cancer treatment.Journal of experimental & clinical cancer research : CR · 2026
    Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Emily K NinmerDepartment of Surgery/Division of Surgical Oncology and the Human Immune Therapy Center, Cancer Center, University of Virginia, Charlottesville, Virginia, USA.ORCID 0009-0001-2973-9883
Hong ZhuDepartment of Public Health Sciences, University of Virginia, Charlottesville, Virginia, USA.
Kimberly A Chianese-BullockDepartment of Surgery/Division of Surgical Oncology and the Human Immune Therapy Center, Cancer Center, University of Virginia, Charlottesville, Virginia, USA.
Craig L SlingluffDepartment of Surgery/Division of Surgical Oncology and the Human Immune Therapy Center, Cancer Center, University of Virginia, Charlottesville, Virginia, USA.

Funding

Women's Oncology Program - WONP30CA044579 · NCI · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI Dina Gould Halme · 1987 to 2026
$72.1M
ZACOPRIDE VS METOCLOPRAMIDE--EFFECT ON LOWER ESOPHAGEAL SPHINCTERM01RR000847 · NCRR · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI KRAMER, CHRISTOPHER M. · 1985 to 2010
$48.1M
MELANOMA VACCINES USING MHC-ASSOCIATED PEPTIDESR01CA057653 · NCI · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI SLINGLUFF, CRAIG LEE · 1997 to 2012
$3.4M
Cancer Research InstituteNCI NIH HHS P30 CA044579NCI NIH HHS P30 CA44579NCI NIH HHS R01 CA057653NCI NIH HHS R01 CA57653NCRR NIH HHS M01 RR000847NIH HHS M01 RR00847Philanthropic gift (Mr. and Mrs. William Goodwin)University of Virginia (Pratt Fund, Rebecca Harris Fellowship)
6 · The paper itself

Abstract

In this post-hoc analysis, we report long-term clinical outcomes of a randomized phase II clinical trial (Mel39, NCT00938223) that tested the immunogenicity of two multipeptide vaccines designed to stimulate CD8

Indexed as

Cancer VaccinesMelanomaSkin NeoplasmsAdultAgedCD8-Positive T-LymphocytesFemaleFollow-Up StudiesHumansMaleMiddle AgedTreatment OutcomeVaccinationVaccines, SubunitCancer VaccinesVaccines, Subunitimmunotherapymelanomapeptide vaccineshared antigens

Identifiers

PMID40536492
PMCPMC12407048

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.